Loading clinical trials...
Loading clinical trials...
A Phase I Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD8965 Following Single and Multiple Ascending Dose Administration to Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
Conditions
Interventions
AZD8965
Placebo
Locations
1
United States
Research Site
Glendale, California, United States
Start Date
August 2, 2024
Primary Completion Date
June 1, 2025
Completion Date
November 15, 2025
Last Updated
December 11, 2025
NCT07310901
NCT06342713
NCT07401472
NCT07412353
NCT07280858
NCT07300189
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions